Research Library

Larger trucks and SUVs with powerful, high-displacement engines are the low-hanging fruit for any policymaker seeking the most efficient path to reducing gasoline use and the associated emissions.

Fellows Gabriel Collins and Jim Krane argue in this issue brief that despite changes in U.S.-Persian Gulf trade relations, the U.S. retains an enduring interest in preserving political stability and securing oil flows from the region.

The high-growth, high-tech sector appears poised to dramatically grow. U.S. policy to support this sector could enhance and hasten its rise, or could destroy a new American dream.

China Studies fellow Steve Lewis offers an approach to increase and strengthen the number of “contact points” between the Trump administration and the future leadership of China.

To harness the power of the market for ideas, the federal government must fund the U.S. patent office to 21st century levels and enhance the rights of patent owners.

In order to increase the capacity of American children to become productive citizens and compete in a global economy, it is vital that future federal policies include a focus on improving children’s brain development, writes health policy scholar Quianta Moore.

A critical reassessment of NASA’s current programs and future is essential to ensure the nation’s continued leadership role in human spaceflight, writes senior fellow George Abbey.

U.S. energy policy is evolving under President Trump, and the changes will affect trade, foreign policy and relations with key global energy suppliers, including the Gulf Cooperation Council member countries. Fellow Jim Krane and Elsie Hung explore how U.S. energy and climate policies could change under the Trump administration and what implications these could have in the U.S. itself, for energy markets globally and for the GCC states.

Ambassador Edward P. Djerejian, director of the Baker Institute, makes the case for a comprehensive North American strategy in which the U.S., Mexico and Canada act in concert to become the global superpower of the 21st century.

High cancer drug prices significantly contribute to health care costs in the United States, with the average annual price of new cancer drugs increasing from less than $10,000 before 2000 to $145,000 in 2015. Baker Institute fellows Hagop M. Kantarjian and Vivian Ho highlight this issue and propose possible solutions.